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OBJECTIVES This study sought to examine whether oral intake of alpha-tocopherol, an antioxidant, could
improve endothelium-dependent vasorelaxation in patients with high remnant lipoproteins
levels.
BACKGROUND Remnant lipoproteins are known to be atherogenic and impair endothelium-dependent
arterial relaxation, but the underlying mechanisms remain unclear. Oxidative stress is a
common feature of various risk factors for atherosclerosis.
METHODS Flow-mediated vasodilation of the brachial artery during reactive hyperemia was
examined by high resolution ultrasound technique before and at the end of 4 weeks
treatment with oral administration of alpha-tocopherol acetate (300 IU/day) or placebo,
which was randomly assigned, in 40 patients with high serum levels of remnants and in
30 patients with low remnants levels in the fasting state (.75th percentile and ,25th
percentile, respectively, of the distribution of remnants levels in 150 consecutive
hospitalized patients).
RESULTS Before treatment, flow-mediated vasodilation was lower in patients with high remnants levels
than in those with low levels (4.1 6 0.3% vs. 6.0 6 0.5%, p , 0.01). Treatment with
alpha-tocopherol but not with placebo significantly increased flow-mediated dilation in
patients with high remnants levels (7.5 6 0.4% after alpha-tocopherol vs. 4.2 6 0.4% after
placebo, p , 0.01). In patients with low remnants levels, alpha-tocopherol was not effective.
The beneficial effect with alpha-tocopherol in high remnants patients was associated with
decrease in plasma levels of thiobarbituric acid reactive substances, an indicator of lipid
peroxidation (6.6 6 0.3 nmol/ml before alpha-tocopherol vs. 4.6 6 0.3 after alpha-
tocopherol, p , 0.05).
CONCLUSIONS Alpha-tocopherol improved impairment of endothelium-dependent vasodilation in patients
with high remnants levels. The increase in oxidative stress may at least partly contribute to
endothelial vasomotor dysfunction in patients with high remnants levels. (J Am Coll Cardiol
1999;33:1512–8) © 1999 by the American College of Cardiology
There is increasing evidence that triglycerides and
triglycerides-rich lipoproteins are atherogenic (1–3). We
recently showed that remnant lipoproteins have an impor-
tant and causative role in the impairment of endothelium-
dependent vasodilation, an early sign of atherosclerosis, in
patients with postprandial hypertriglyceridemia (4,5). How-
ever, the underlying mechanisms for the remnants-induced
endothelial dysfunction remain to be determined. Recent
reports (6–10) showed that the increase in oxidative stress is
a common feature of various risk factors for atherosclerosis
and that oxidative stress mediated by reactive oxygen species
has a causative role in endothelial dysfunction not only in
patients with coronary artery disease but also in patients
with coronary risk factors and free of obvious coronary
atherosclerosis. Thus, we hypothesized that the increase in
oxidative stress may also participate in endothelial dysfunc-
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tion in patients with high levels of remnant lipoproteins.
Flow-mediated vasodilation in brachial artery has been used
as a noninvasive method to assess endothelial function
(7,8,11,12).
Thus, this study examined effects of oral administration
of alpha-tocopherol, an antioxidant, for four weeks on
endothelial vasomotor functions in brachial artery of pa-
tients with high and low serum levels of remnants lipopro-
teins in a randomized and placebo-controlled manner.
METHODS
Study population. The study population included 40 con-
secutive patients with high serum levels of remnant lipopro-
teins and 30 consecutive patients with low remnants levels,
all of whom underwent diagnostic coronary angiography for
atypical chest pain in Kumamoto University Hospital. This
study excluded patients treated with lipids-lowering drugs,
pharmacologic doses of other antioxidants, angiotensin-
converting enzyme inhibitors or calcium channel blocking
agents at least a month before and during this study.
Clinical features of the study patients are shown in Table 1.
Beta-adrenergic blocking agents, nitrates or diuretics were
used in some of the study subjects with coronary artery
disease or hypertension before and throughout this study,
but there was no significant difference in the rates of each of
these medications used among the study subgroups. Type
III hyperlipoproteinemia was found in two of the patients
with high remnants levels. Diabetes mellitus was compli-
cated in 14 of the patients with high remnants levels. The
exact cause of high remnants levels was unknown in the
remaining patients. Patients with previous myocardial in-
farction, congestive heart failure, valvular heart disease or
other serious diseases were also excluded from this study.
High and low serum levels of remnants lipoproteins were
determined as levels .75th percentile (.5.1 mg cholester-
ol/dl) and ,25th percentile (,2.4 mg/dl), respectively, on
the basis of the distribution of serum remnants levels in 150
consecutive patients hospitalized in the Cardiology Section
of this hospital, as described in our previous report (4).
Written informed consent was obtained from all patients
before the study. This study was in agreement with the
guidelines approved by the ethics committee at our institu-
tion.
Study protocol. The study patients were randomly as-
signed to have oral intake for 4 weeks of alpha-tocopherol
acetate (300 IU/day, 20 and 15 patients with high and low
remnants levels, respectively) or placebo (similar-appearing
placebo tablet, 20 and 15 patients with high and low
remnants levels, respectively) using a random number table
generated by a computer. All of the patients were blinded to
the content of the tablet. Our preliminary data showed that
this dose of alpha-tocopherol increased its content in the
isolated remnants by two- or threefold. They were advised
to adhere to their usual diet and lifestyle throughout four
weeks. All of the study patients completed the trial. Mea-
surements of vasoactivity in the brachial artery and blood
sampling were performed in overnight fasting state on the
same morning before and at the end of the treatment, in
exactly the same manner before and at the end of the
treatment. All medications were withdrawn 12 h before the
measurements.
Table 1. Clinical Characteristics of Alpha-Tocopherol– and Placebo-Treated Groups in Patients
With High and Low Remnants Levels
High Remnants (n 5 40) Low Remnants (n 5 30)
Alpha-Tocopherol
(n 5 20)
Placebo
(n 5 20)
Alpha-Tocopherol
(n 5 15)
Placebo
(n 5 15)
Age (yr) 58.3 6 2.1 59.6 6 2.1 61.7 6 2.3 60.8 6 1.9
Men/women 8/12 9/11 6/9 7/8
Smokers 8 (40.0) 7 (35.0) 6 (40.0) 6 (40.0)
Hypercholesterolemia 7 (35.0) 8 (40) 3 (20.0) 3 (20.0)
Hypertension 6 (30.0) 7 (35.0) 4 (26.7) 5 (33.3)
Diabetes mellitus 7 (35.0) 7 (35.0) 3 (20.0) 3 (20.0)
Coronary artery disease 3 (15.0) 3 (15.0) 2 (13.3) 2 (13.3)
One-vessel disease 1 (5.0) 2 (10.0) 2 (13.3) 1 (6.7)
Two-vessel disease 2 (10.0) 1 (5.0) 0 1 (6.7)
Body mass index (kg/m2) 23.3 6 2.9 23.4 6 2.8 22.9 6 1.7 22.8 6 1.9
Values are expressed as mean value 6 SE (in age and body mass index) and number of patients. Values in parentheses indicate
% of total patients. Smoker, $10 cigarettes/day for 10 years; hypercholesterolemia $240 mg/dl of serum cholesterol levels;
hypertension, blood pressure $140/90 mm Hg or on an antihypertensive medication; diabetes mellitus, fasting blood glucose
$140 mg/dl or on an antidiabetic medication.
Abbreviations and Acronyms
apo 5 apolipoprotein
LDL 5 low density lipoproteins
TBARS 5 thiobarbituric acid reactive substances
VLDL 5 very low density lipoproteins
1513JACC Vol. 33, No. 6, 1999 Kugiyama et al.
May 1999:1512–8 Alpha-Tocopherol and Remnant Lipoproteins
Measurements of flow-mediated dilation in brachial ar-
tery. Vasodilator responses in the brachial arteries were
measured by use of B-mode ultrasound images with a
7.5-MHz linear array transducer (SSH-160A ultrasound
system, Toshiba Corp., Tokyo, Japan) as validated previ-
ously by our and other studies (7,8,11,12). Measurements
were performed by two observers who were blinded to the
protocols of the study and the subject grouping. The
brachial artery was scanned in the antecubital fossa in a
longitudinal fashion. Optimal brachial artery images were
obtained between 1 and 5 cm above the antecubital crease.
This location was marked, and all subsequent images were
obtained at the same location. The exact distance of the
measured point of the skin surface from the antecubital
crease was recorded in each study subject to ensure that the
same point of the brachial artery was measured 4 weeks
later. Gain setting was optimized at the beginning of the
study and was kept constant throughout the recording
period. After baseline measurements of the diameter and
flow velocity in the brachial artery, a blood pressure cuff
placed around the forearm was inflated with a pressure of
250 to 300 mm Hg for 5 min, and then the cuff was
released. Diameter measurements during the reactive hyper-
emia were taken 45 to 90 s after the cuff deflation. Then,
sublingual nitroglycerin (300 mg) was administered, and
3 min later the measurements were repeated. Images were
recorded on a super-VHS videocassette recorder (model
BR-S601M, Victor Corp., Tokyo, Japan), and brachial
arterial diameters were measured from the tape with ultra-
sonic calipers, as described previously (8,11,12). Responses
of the vessel diameters to the reactive hyperemia and
nitroglycerin were expressed as a percentage increase in the
diameter from the baseline value. The diameter responses
were assessed at three points along a 10-mm length of the
artery, and the diameter responses were averaged. Blood
flow was calculated by multiplying the velocity–time integral
of the Doppler flow signal by heart rate and the vessel
cross-sectional area. Increase in brachial blood flow was
calculated as a maximum flow recorded in the first 15 s after
the cuff deflation and was expressed as a percentage increase
in the flow from the baseline value.
Measurements of remnant lipoproteins levels. Remnant
lipoproteins levels were measured in overnight fasting se-
rum. Remnant lipoproteins were isolated by the application
of the fasting serum to the immunoaffinity mixed gel that
contained anti–apolipoprotein (apo)A-1 and anti–apoB-100
monoclonal antibodies (Japan Immunoresearch Laborato-
ries, Takasaki, Japan) as validated in our previous reports
(4,5,13). Cholesterol concentrations in the isolated fraction
were measured by the enzymatic method (4,5,13). Accord-
ing to the analyses with sodium dodecyl sulfate–
polyacrylamide gel electrophoresis, elution profiles with
high performance liquid chromatography, agarose gel elec-
trophoretograms, electron photomicrographs and composi-
tions of lipids and apolipoproteins, the lipoproteins isolated
by this method mainly consisted of remnants of very low
density lipoproteins (VLDL) (data not shown), as demon-
strated in our previous reports (4,5,13). The fasting rem-
nants levels, measured in this study, were found to be well
correlated with the postprandial levels, as shown in our
previous study (4).
Plasma levels of alpha-tocopherol and thiobarbituric acid
reactive substances (TBARS) and measurement of sus-
ceptibility of remnants to oxidative modification. Blood
sampling was performed just before the ultrasound study.
The plasma levels of alpha-tocopherol were determined by
high performance liquid chromatography (14). The plasma
level of TBARS, an indicator of lipid peroxides in plasma,
was determined as previously described (15,16). Briefly,
2.0 ml of trichloroacetic acid–thiobarbituric acid–HCl re-
agent was added to 1.0 ml of sample and vortexed. To
minimize peroxidation during the assay procedure, buty-
lated hydroxytoluene was added to the thiobarbituric acid
reagent mixture. The results were expressed as malondial-
dehyde equivalent content (nmol malondialdehyde/ml plas-
ma). The susceptibility of remnants to oxidative modifica-
tion was determined by measuring Cu21-induced formation
of conjugated dienes. The conjugated dienes formation in
remnants was assayed by monitoring the change in absor-
bance at 234 nm in a spectrophotometer as described
previously (17).
Statistical analysis. Data are expressed as mean 6 SEM.
The effects of the treatment on lipids profiles, hemodynamic
parameters, brachial arterial parameters and plasma alpha-
tocopherol and TBARS levels were compared by two-way
analysis of variance with repeated measures followed by post
hoc testing with Scheffe´ test by computer statistical software
package SAS, version 6.12 (Cary, North Carolina). Differ-
ence between two means among the subgroups were per-
formed by two-tailed paired or unpaired Student t test, as
appropriate. Difference in frequencies of risk factors among
the subgroups was compared using chi-square test. Statis-
tical significance was defined as p , 0.05.
RESULTS
Clinical characteristics of study patients. Clinical features
and lipids profiles before treatment were comparable be-
tween alpha-tocopherol–treated patients and placebo-
treated patients in either patients with high or low remnants
levels (Tables 1 to 3). Levels of total cholesterol and
triglycerides were significantly higher in patients with high
remnants levels than in those with low remnants levels (total
cholesterol, 212 6 15 mg/dl in high remnants patients vs.
186 6 11 mg/dl in low remnants patients, p , 0.05;
triglycerides, 201 6 19 mg/dl in high remnants patients vs.
101 6 16 mg/dl in low remnants patients, p , 0.01). After
treatments, levels of remnants cholesterol, total cholesterol,
high density lipoprotein cholesterol, and triglycerides were
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not significantly changed as compared with those before
treatments in each of the subgroups (Tables 2 and 3).
Flow-mediated dilation in brachial artery. Before treat-
ment, heart rates, mean blood pressure, baseline arterial
diameter of brachial artery, baseline blood flow of brachial
artery and percentage increase in the blood flow during
reactive hyperemia were comparable between alpha-
tocopherol–treated patients and placebo-treated patients in
either patients with high or those with low remnants levels
(Tables 2 and 3). Flow-mediated dilation of the brachial
artery before treatment was significantly lower in patients
with high remnant lipoproteins levels as compared with that
in those with low remnants levels, but it was comparable
between alpha-tocopherol and placebo groups in patients
with high remnants levels as well as those with low
remnants levels (percentage increase in arterial diameter
from baseline, 4.1 6 0.2% in high remnants patients with
alpha-tocopherol vs. 4.2 6 0.4% in high remnants patients
with placebo, p 5 0.67; 6.2 6 0.7%* in low remnants
patients with alpha-tocopherol vs. 5.8 6 0.3%† in low
remnants patients with placebo, p 5 0.21; *p , 0.01 vs.
high remnants patients with alpha-tocopherol, †p , 0.01
vs. high remnants patients with placebo). The dilator
response to sublingual nitroglycerin before treatment was
comparable among the subgroups (Tables 2 and 3).
After treatment, neither alpha-tocopherol treatment nor
placebo treatment affected heart rates, mean blood pressure,
baseline arterial diameter of brachial artery, baseline blood
flow of brachial artery and percentage increase in the blood
flow during reactive hyperemia in both patients with high
and those with low remnants levels (Tables 2 and 3).
Treatment with alpha-tocopherol significantly increased the
flow-mediated dilation as compared with placebo treatment
in patients with high remnants lipoproteins levels (Fig. 1).
Table 2. Effects of Treatments in Patients With High Remnants Levels
Alpha-Tocopherol (n 5 20) Placebo (n 5 20) Two-Way Analysis
of Variance
p ValueBefore After Treatment Before After Treatment
Remnants cholesterol (mg/dl) 6.5 6 1.2 6.2 6 1.1 6.4 6 0.5 6.3 6 0.3 NS
Total cholesterol (mg/dl) 214 6 9.9 213 6 9.3 210 6 10 206 6 23 NS
HDL cholesterol (mg/dl) 49 6 4 50 6 5 49 6 4 51 6 7 NS
Triglyceride (mg/dl) 196 6 14 189 6 21 205 6 22 200 6 19 NS
Alpha-tocopherol (mmol/liter) 23 6 1.2 51 6 4.2* 25 6 1.5 23 6 1.9 , 0.01
TBARS (nmol MDA/ml) 6.6 6 0.3 4.6 6 0.3† 6.3 6 0.3 6.3 6 0.4 , 0.05
Heart rate (beats/min) 61 6 5.3 63 6 4.3 62 6 5.1 62 6 6.5 NS
Mean blood pressure (mm Hg) 88 6 5.2 90 6 7.2 88 6 7.1 90 6 6.4 NS
Resting arterial diameter (mm) 3.90 6 0.19 3.91 6 0.18 3.88 6 0.16 3.89 6 0.21 NS
Resting arterial blood flow (ml/min) 188 6 10 190 6 9 192 6 9 193 6 12 NS
Increase in arterial blood flow (%) 236 6 15 237 6 20 234 6 20 234 6 17 NS
Dilator response to nitroglycerine (%) 17.3 6 5.4 17.4 6 5.7 17.6 6 5.9 17.9 6 7.1 NS
*p , 0.01, †p , 0.05 vs. before alpha-tocopherol using two-way analysis of variance followed by post hoc testing with Scheffe´ test. Values are expressed as mean value 6 SE.
HDL 5 high density lipoprotein; MDA 5 malondialdehyde equivalent content; TBARS 5 thiobarbituric acid reactive substances.
Table 3. Effects of Treatments in Patients With Low Remnants Levels
Alpha-Tocopherol (n 5 15) Placebo (n 5 15) Two-Way Analysis
of Variance
p ValueBefore After Treatment Before After Treatment
Remnants cholesterol (mg/dl) 1.8 6 0.4 1.9 6 0.5 1.7 6 0.9 1.7 6 0.1 NS
Total cholesterol (mg/dl) 186 6 11 187 6 15 185 6 12 182 6 14 NS
HDL cholesterol (mg/dl) 53 6 6 54 6 9 52 6 3 52 6 3 NS
Triglyceride (mg/dl) 101 6 19 95 6 22 103 6 13 101 6 16 NS
Alpha-tocopherol (mmol/liter) 21 6 1.9 47 6 5.5* 23. 6 1.7 20 6 1.1 , 0.01
TBARS (nmol MDA/ml) 5.9 6 0.4 4.4 6 0.3† 6.0 6 0.2 6.2 6 0.5 , 0.05
Heart rate (beats/min) 61 6 6 62 6 5 60 6 5 60 6 9 NS
Mean blood pressure (mm Hg) 87 6 6 87 6 7 87 6 7 90 6 8 NS
Resting arterial diameter (mm) 3.90 6 0.22 3.91 6 0.21 3.91 6 0.18 3.90 6 0.20 NS
Resting arterial blood flow (ml/min) 191 6 14 191 6 11 192 6 13 191 6 15 NS
Increase in arterial blood flow (%) 232 6 16 232 6 16 230 6 18 230 6 20 NS
Dilator response to nitroglycerin (%) 17.9 6 6.2 18.1 6 5.9 17.6 6 6.1 17.9 6 7.7 NS
*p , 0.01, †p , 0.05 vs. before alpha-tocopherol using two-way analysis of variance followed by post hoc testing with Scheffe´ test. Values are expressed as mean value 6 SE.
Abbreviations as in Table 2.
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In patients with low remnants levels, alpha-tocopherol did
not significantly increase the flow-mediated dilation as
compared with placebo treatment (Fig. 1). Alpha-
tocopherol treatment also improved flow-mediated dilation
in a subgroup of normocholesterolemic and nondiabetic
patients (,240 mg/dl of serum cholesterol levels,
,140 mg/dl of fasting blood glucose, no lipids-lowering
medication and no antidiabetic medication) with high
remnant lipoproteins levels (percentage increase in the
arterial diameter, 4.6 6 0.3% before treatment vs. 7.8 6
0.8% after treatment, n 5 10, p , 0.01). Neither alpha-
tocopherol nor placebo treatment changed the dilator re-
sponse to nitroglycerin in either patients with high or those
with low remnants levels (Tables 2 and 3).
Levels of alpha-tocopherol and TBARS and oxidative
susceptibility of remnants. Plasma levels of alpha-
tocopherol were significantly increased after alpha-tocopherol
treatment in both patients with high and those with low
remnant lipoproteins levels, whereas the levels were not signif-
icantly changed after placebo treatment (Tables 2 and 3).
Treatment with alpha-tocopherol but not with placebo signif-
icantly decreased plasma levels of TBARS in both patients
with high and those with low remnants levels (Tables 2 and 3).
The lag time for Cu21-induced conjugated dienes formation
of remnant lipoproteins was longer after treatment with alpha-
tocopherol as compared with that after placebo (480 6 58 min
after alpha-tocopherol vs. 230 6 18 min after placebo, n 5 5,
p , 0.01).
DISCUSSION
The present study demonstrated that flow-mediated vaso-
dilation in brachial arteries was impaired in patients with
high remnant lipoproteins levels, a result which is consistent
with data observed in human coronary arteries as shown
in our previous report (4). The present study further
showed that oral administration of alpha-tocopherol for
four weeks increased flow-mediated vasodilation in brachial
artery of patients with high remnant lipoproteins levels as
compared with placebo treatment. The present study also
showed that alpha-tocopherol treatment did not affect
vasodilation in response to nitroglycerin, an endothelium-
independent vasodilator, in either group of patients. Thus,
the present study indicates that alpha-tocopherol improved
endothelium-dependent arterial dilation in patients with
high remnant lipoproteins levels. The improvement of the
endothelial dysfunction is unlikely to be due to changes of
lifestyle and habits, since profiles of plasma lipids, blood
pressure and habits were not altered after treatment as
compared with those before treatment, and placebo treat-
ment in the otherwise identical protocol as alpha-tocopherol
treatment did not affect the endothelial vasomotor function.
Oxidative stress and remnant lipoproteins. Alpha-
tocopherol, a lipid soluble antioxidant, has been shown to
protect endothelial cells against oxidative damage (18–21).
Previous reports showed that alpha-tocopherol supplemen-
tation restored endothelial function in parallel with suppres-
sion of lipid peroxidation in low density lipoproteins (LDL)
in experimental hypercholesterolemic animals (19,21). In
this regard, the present study also showed that the improve-
ment of endothelium-dependent vasodilation was associated
with decrease in plasma TBARS levels, an indicator of lipid
peroxidation, after alpha-tocopherol treatment in patients
with high remnants levels. This strongly suggests that the
beneficial effect of alpha-tocopherol, as shown in the present
study, was at least partly mediated through prevention of
endothelial function from oxidative stress-induced injury in
patients with high remnant lipoproteins levels. We have
previously shown that oxidatively modified LDL causes
endothelial dysfunction and has an important role in ath-
erosclerotic impairment of various endothelial functions
(15). It has recently been reported that oxidatively modified
remnant lipoproteins caused greater formation of foam cells
in in vitro experiments than native remnant lipoproteins
(22), suggesting that oxidized remnant lipoproteins may
also play an important role in atherogenesis in hyperlipid-
emic patients. Our preliminary study showed that oxidized
remnant lipoproteins exhibited greater impairment of
endothelium-dependent relaxation of isolated rabbit aortas
than native remnants (unpublished data). In patients with
high remnant lipoproteins levels, the prolonged retention of
remnants in the circulation, as a result of the delayed hepatic
uptake and/or the increased hepatic secretion of VLDL
(23,24), may augment susceptibility of remnants to oxida-
tive modification in the arterial intima, leading to increase in
injurious effects of remnants on endothelial function.
Among antioxidants, alpha-tocopherol is the major antiox-
idant contained in lipoproteins (25). Thus, the improve-
Figure 1. Percentage increase in brachial arterial diameter from
baseline during reactive hyperemia before and after treatment with
alpha-tocopherol (open circles) or placebo (closed circles) in
patients with high remnant lipoproteins levels (n 5 20 patients in
each treatment) and in those with low remnants levels (n 5 15
patients in each treatment). Significant effect of alpha-tocopherol
treatment was observed in patients with high remnant lipoproteins
levels as compared with that of placebo but not in those with low
remnants levels (by two-way analysis of variance followed by post
hoc testing with Scheffe´ test).
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ment of endothelial function by alpha-tocopherol in the
present study may at least partly occur as a result of
protection of remnant lipoproteins against oxidative modi-
fication in the arterial intima.
In patients with low levels of remnant lipoproteins, the
decrease in TBARS after alpha-tocopherol treatment was
not associated with an increase in the endothelium-
dependent vasodilation as compared with placebo, though
endothelium-dependent dilation in these patients was not
impaired before treatment on the basis of our data in healthy
adults. The results are in agreement with those in the
previous reports (7–10) showing that the beneficial effect of
ascorbic acid, another antioxidant, on vasomotor function
was exerted in only patients with impaired endothelium-
dependent dilation. This presumably may be due to less
oxidative damage on endothelial function in patients with
low levels of remnant lipoproteins. However, it cannot be
completely excluded that alpha-tocopherol exerted the ben-
eficial effects on endothelial functions in high levels of
remnant lipoproteins independent of its antioxidant action.
In this context, it is interesting that alpha-tocopherol is
capable of suppressing activity of protein kinase C, which is
suggested to play a role in the impairment of endothelium-
dependent vasorelaxation in atherosclerotic arterial walls
(26,27).
Hypercholesterolemia and diabetes mellitus, independent
factors of endothelial dysfunction, coexisted with high levels
of remnant lipoproteins, as shown in the present and
previous studies (4,28). Thus, there is a possibility that the
beneficial effect of alpha-tocopherol on endothelial function
in patients with high remnants levels may result from the
improvement of endothelial function in patients with hy-
percholesterolemia and/or diabetes mellitus. However, this
possibility cannot explain all of the present data, since
beneficial effect of alpha-tocopherol was observed also in
normocholesterolemic and nondiabetic patients with high
remnants levels, as shown in the present study.
Measurement of remnant lipoproteins levels. Remnant
lipoproteins are known to have heterogeneous properties
(4,29). Thus, simple and reliable methods to separate
remnant lipoproteins had not been established. The current
method with immunoaffinity mixed gel containing anti–
apoA-1 and anti–apoB-100 monoclonal antibodies has been
reported to be capable of isolating apoE-rich VLDL parti-
cles containing apoB-100 together with chylomicron rem-
nants containing apoB-48, neither of which binds to the
immunoaffinity gel (4,5,13,29). This unique anti–apoB-100
monoclonal antibody has been shown to recognize apoB-
100 in LDL and most VLDL but not in apoE-enriched
VLDL (13). Remnants levels in the postprandial state may
be a better predictor (2,30). However, we have recently
shown that fasting levels of remnant lipoproteins are an
independent predictor for the presence of endothelial dys-
function in human coronary arteries (4). Thus, the measure-
ment of fasting levels of remnant lipoproteins using the
current immunoaffinity gel seems to have a good theoretical
basis and could be useful to quantify levels of the athero-
genic triglyceride-rich lipoproteins.
Previous studies. The results of the present study are
compatible with those of previous studies showing beneficial
effects of either vitamin C (7–10), a water soluble antioxi-
dant, or alpha-tocopherol (31) and probucol (32), lipid
soluble antioxidants on the endothelial function. However,
Gilligan and others (33,34) showed negative results on the
effects of antioxidant vitamins. Different backgrounds, such
as the associated risk factors in the study population, may
possibly cause the incompatible results among the studies.
Study limitations. Many assays are available for measure-
ment of lipid peroxidation, but no single assay accurately
reflects free radical generation. Thiobarbituric acid reactive
substances measurement is also susceptible to artifacts
caused by variation in sample lipid content and iron con-
tamination of reagents. In the present study, we prevented
auto-oxidation of the samples by addition of butylated
hydroxytoluene to the samples.
Conclusions. The present study showed that alpha-
tocopherol improved impairment of endothelium-
dependent vasodilation in patients with high remnant li-
poproteins levels. Oxidative stress may at least partly play a
role in the abnormal endothelial vasomotor function in
patients with high remnant lipoproteins levels.
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